How to use stones from other hills to polish our own jade: evaluating standardized treatment of intracerebral hemorrhage in China based on the current international clinical research

doi:10.3969/j.issn.1672-6731.2021.02.001

Abstract

Abstract:

Spontaneous intracerebral hemorrhage (ICH) has high mortality and disability rate, but the effective treatment strategy is still lacking. There is a certain gap between the Chinese and the international ICH research. In recent years, a series of international clinical studies have explored the ICH treatment based on different strategies, which provides very important references for the research and standardized treatment of ICH in China. High-quality clinical trials are necessary to exchange between China and other countries. Department of Neurosurgery of West China Hospital, Sichuan University is carrying out Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial 3 (INTERACT3) and preparing to carry out International Surgical Trial in Intracerebral Haemorrhage Ⅲ (STICH Ⅲ), hoping to promote the progress of ICH research in China.

Key words: Cerebral hemorrhage, Therapy, Clinical trial, China, Review

摘要：

自发性脑出血病死率和病残率较高，但缺乏有效的治疗策略。我国的脑出血相关研究与国际先进水平存在一定差距。近年国际上一系列临床研究从不同角度探讨脑出血的治疗方式，对我国脑出血研究和规范化治疗具有十分重要的参考价值。我国的脑出血临床治疗经验和研究成果要想走向世界，必须开展高质量的临床试验。四川大学华西医院神经外科正在开展INTERACT3试验，以及准备开展STICHⅢ试验，希望能够推动中国脑出血研究事业的进步。

关键词: 脑出血, 治疗, 临床试验, 中国, 综述

YOU Chao. How to use stones from other hills to polish our own jade: evaluating standardized treatment of intracerebral hemorrhage in China based on the current international clinical research[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(2): 67-70.

游潮. 他山之石何以攻玉：从脑出血国际临床研究现状看我国的规范化治疗[J]. 中国现代神经疾病杂志, 2021, 21(2): 67-70.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.02.001

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I2/67

References

[1] Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage:current approaches to acute management[J]. Lancet, 2018, 392:1257-1268.
[2] Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH):a randomised trial[J]. Lancet, 2005, 365:387-397.
[3] Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM; STICH Ⅱ Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH Ⅱ):a randomised trial[J]. Lancet, 2013, 382:397-408.
[4] Ziai W, Nyquist P, Hanley DF. Surgical strategies for spontaneous intracerebral hemorrhage[J]. Semin Neurol, 2016, 36:261-268.
[5] Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, Bistran-Hall AJ, Mayo SW, Keyl P, Gandhi D, Morgan TC, Ullman N, Mould WA, Carhuapoma JR, Kase C, Ziai W, Thompson CB, Yenokyan G, Huang E, Broaddus WC, Graham RS, Aldrich EF, Dodd R, Wijman C, Caron JL, Huang J, Camarata P, Mendelow AD, Gregson B, Janis S, Vespa P, Martin N, Awad I, Zuccarello M; MISTIE Investigators. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE):a randomised, controlled, open-label, phase 2 trial[J]. Lancet Neurol, 2016, 15:1228-1237.
[6] Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE Ⅲ Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE Ⅲ):a randomised, controlled, open-label, blinded endpoint phase 3 trial[J]. Lancet, 2019, 393:1021-1032.
[7] Awad IA, Polster SP, Carrión-Penagos J, Thompson RE, Cao Y, Stadnik A, Money PL, Fam MD, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson AP, Camarata PJ, Caron JL, Harrigan MR, Gregson BA, Mendelow AD, Zuccarello M, Hanley DF; MISTIE Ⅲ Trial Investigators. Surgical performance determines functional outcome benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) procedure[J]. Neurosurgery, 2019, 84:1157-1168.
[8] Vespa P, Hanley D, Betz J, Hoffer A, Engh J, Carter R, Nakaji P, Ogilvy C, Jallo J, Selman W, Bistran-Hall A, Lane K, McBee N, Saver J, Thompson RE, Martin N; ICES Investigators. ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for brain hemorrhage:a multicenter randomized controlled trial[J]. Stroke, 2016, 47:2749-2755.
[9] Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT):a randomised pilot trial[J]. Lancet Neurol, 2008, 7:391-399.
[10] Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J]. N Engl J Med, 2013, 368:2355-2365.
[11] Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46:2032-2060.
[12] Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage[J]. N Engl J Med, 2016, 375:1033-1043.
[13] Toyoda K, Koga M, Yamamoto H, Foster L, Palesch YY, Wang Y, Sakai N, Hara T, Hsu CY, Itabashi R, Sato S, Fukuda-Doi M, Steiner T, Yoon BW, Hanley DF, Qureshi AI; ATACH-2 Trial Investigators. Clinical outcomes depending on acute blood pressure after cerebral hemorrhage[J]. Ann Neurol, 2019, 85:105-113.
[14] Kapinos G, Hanley DF Jr. The systolic blood pressure sweet spot after intracerebral hemorrhage:130 mm Hg[J]? Neurology, 2018, 91:495-496.
[15] Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2):an international randomised, placebo-controlled, phase 3 superiority trial[J]. Lancet, 2018, 391:2107-2115.
[16] Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD; i-DEF Investigators. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF):a multicentre, randomised, placebo-controlled, double-blind phase 2 trial[J]. Lancet Neurol, 2019, 18:428-438.
[17] Li Q, Zhang G, Huang YJ, Dong MX, Lv FJ, Wei X, Chen JJ, Zhang LJ, Qin XY, Xie P. Blend sign on computed tomography:novel and reliable predictor for early hematoma growth in patients with intracerebral hemorrhage[J]. Stroke, 2015, 46:2119-2123.
[18] Li Q, Zhang G, Xiong X, Wang XC, Yang WS, Li KW, Wei X, Xie P. Black hole sign:novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage[J]. Stroke, 2016, 47:1777-1781.
[19] Li Q, Liu QJ, Yang WS, Wang XC, Zhao LB, Xiong X, Li R, Cao D, Zhu D, Wei X, Xie P. Island sign:an imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage[J]. Stroke, 2017, 48:3019-3025.

Please choose a citation manager

Content to export